Horizon Kinetics Asset Management LLC Has $1.87 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Horizon Kinetics Asset Management LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,718 shares of the company’s stock after buying an additional 250 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,872,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Envestnet Asset Management Inc. grew its stake in Novo Nordisk A/S by 1.4% in the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after acquiring an additional 58,935 shares during the period. Raymond James & Associates lifted its holdings in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after purchasing an additional 36,223 shares in the last quarter. Natixis Advisors LLC grew its position in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. International Assets Investment Management LLC increased its stake in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Finally, DSM Capital Partners LLC raised its holdings in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 0.5 %

Shares of NVO stock opened at $104.56 on Tuesday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a 50-day simple moving average of $114.83 and a two-hundred day simple moving average of $128.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $469.22 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 1.35 and a beta of 0.42.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NVO. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.